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Exacerbations of chronic obstructive pulmonary disease (COPD) impair health-related quality
of life (HRQoL). It is unknown whether exacerbations requiring hospitalisation have an impact
on HRQoL.
611 ambulatory COPD patients were prospectively identified. The average age (SD) was 65.5
(8.6), FEV1 (SD) was 52% (14%) of the predicted value. All patients completed the Saint Geor-
ge’s Respiratory Questionnaire (SGRQ) and the Medical Outcomes Study Short Form (SF-36)
questionnaire at the beginning of the study. After five years of follow-up, the 391 survivors
again completed these HRQoL instruments.
No changes in HRQoL were observed among patients not hospitalised for COPD exacerba-
tions. Those hospitalised during follow-up experienced significant declines in HRQoL. The
largest changes were observed among patients with 3 hospitalisations, with a 13.6 unit
increase in the total SGRQ and a 10.5 unit decrease in the physical component summary scale
of the SF-36. Similar changes were observed among patients with FEV1 50% at baseline. In the
multivariate analysis, after adjustment by FEV1%, age, comorbidities, and HRQoL in the respec-
tive HRQoL domain at baseline, hospitalisations were an independent predictor of the change
in HRQoL.
Hospitalisations for exacerbations of COPD have an independent and negative impact on the
evolution of HRQoL, regardless of COPD severity.
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Chronic obstructive pulmonary disease (COPD) is a disorder
characterised by chronic airway obstruction that worsens.
1202 Cristo´bal Esteban et al.over time and that usually affects multiple systems in the
body.1,2 Both the factors cause a progressive decline in
health.3,4
Patients with COPD have periods of clinical stability
punctuated by acute symptomatic episodes that are sepa-
rate from the daily variation in symptoms.5 Patients with
moderate and severe disease experience an average of
2.6e3.4 such episodes per year.6 Although most exacerba-
tions can be treated on an outpatient basis, some are
severe enough to warrant hospitalisation.
Only a few studies have examined the association
between health-related quality of life (HRQoL) and exac-
erbations of COPD. They have generally demonstrated that
poor HRQoL is associated with an increased likelihood of
hospitalisation7 or readmission.8 At the same time, exac-
erbations have been associated with decreased lung func-
tion,9 increased cost of COPD treatment,10 and increased
mortality.11
Following acute COPD exacerbations most patients
experience significant short-term improvements in
HRQoL.12 They also experience long-term, possibly perma-
nent, impairment in HRQoL.13,14 However, some studies
into the association between COPD exacerbations and
HRQoL have some limitations. In some studies HRQoL was
only measured after the exacerbations. Others were clin-
ical trials that do not reflect daily clinical practice.
The research conducted to date has focused on the
consequences of exacerbation in general, grouping patients
treated at ambulatory clinics with those requiring hospi-
talisation. It is not known whether exacerbations requiring
hospitalisation have a similar or greater impact on HRQoL
than less severe exacerbations that are treated on an
outpatient basis, and if the consequences of both types
should be jointly analysed.
We designed this study to determine how hospital-
isations for COPD exacerbation influence HRQoL. We also
wanted to establish whether the severity of COPD influ-
ences the impact of hospitalisations for COPD exacerba-
tions on HRQoL.
Methods
Subjects
We identified all patients under age 80 treated for COPD at
an outpatient clinic affiliated with Hospital Galdakao-
Usansolo between February 1998 and February 1999. This
teaching hospital has a catchment area of 300,000
inhabitants.
Patients were included in the study if they had been
diagnosed with COPD at least six months previously and had
been receiving medical care at one of the hospitals’
outpatient facilities for at least six months. Patients had to
be stable (no increase in respiratory symptoms or changes
in treatment) for six weeks prior to inclusion. Other inclu-
sion criteria were forced expiratory volume in 1 s
(FEV1)< 80% of the predicted value, with an FEV1/forced
vital capacity (FVC) quotient< 70% and a negative bron-
chodilation test with FEV1 change< 200 ml and under 15%
of the baseline value. The functional parameters used were
those obtained following bronchodilation. Patients werenot eligible for the study if they had been diagnosed with
asthma, had extensive pulmonary tuberculosis or neoplastic
processes, were suffering from psychiatric or neurological
problems that might prevent effective collaboration, or had
hearing or other problems that impeded accurate
communication.
Study protocol
Patients were interviewed and examined once soon after
the recruitment. Spirometry was conducted following
criteria from the Spanish Pneumology and Thoracic Surgery
Society (SEPAR)15 with a Master-Scope-PC spirometer (Erich
Jaeger GmbH & Co, KG, Wuerzburg, Germany). Theoretical
values were those prescribed by the European Community
for Steel and Coal.16 Comorbidities were determined by
reviewing the patients’ clinical histories.
HRQoL was assessed using 2 instruments: the generic
Medical Outcomes Study Short Form (SF-36)17 and the Saint
George’s Respiratory Questionnaire (SGRQ),18 which is
specific for respiratory-related HRQoL. We used versions of
both the tests that have been validated in Spanish
populations.19,20
Follow-up
Patients were followed for 5 years. During this period,
patients continued to meet with their primary care physi-
cian and respiratory specialist and follow the treatments
prescribed. No interventions related to this study were
carried out, and the research team did not intervene in
patients’ routine treatment or in the treatment of
exacerbations.
Five years after enrollment, patients were again inter-
viewed, underwent spirometry, and completed the two
HRQoL questionnaires. Follow-up interviews were sched-
uled during times when patients were clinically stable.
Information on hospital admissions due to COPD exac-
erbations in the 2 years prior to patients’ inclusion in the
study as well as during the study was obtained by analysing
the database for our hospital, which is the benchmark
hospital for these patients. In the unusual case that
a patient was admitted to another medical center, we used
admission forms to establish the reason for the admission.
Vital status was determined initially by telephoning
patients and their families. All reported deaths and dates of
deaths were confirmed by reviewing medical records, by
examining the hospital database and public death regis-
tries, or both. Deaths were considered confirmed if the
record matched the subject on name, sex, and date of
birth.
Patients provided verbal informed consent to take part
in the study, which was approved by the research
committee of the Hospital Galdakao-Usansolo.
Statistical analysis
We present mean and standard deviations for continuous
variables and frequencies and percentages for categor-
ical variables. We used the Chi-Square and Fisher’s exact
tests to evaluate associations among categorical
Table 1 Baseline characteristics of study participants by survival status over a 5-year follow-up period.
Survivors 445 (72.8%) Non-survivors 166 (27.2%) p
Age (years) 65.5 (8.6) 70.1 (7.0) <0.0001
FEV1 (L) 1.45 (0.46) 1.13 (0.38) <0.0001
FEV1% 52 (14) 43.6 (14) <0.0001
FEV1/VC (%) 51.1 (10.2) 47.3 (10.1) <0.0001
BMI (kg/m2) 27.9 (4.3) 27.5 (4.3) 0.28
Pack/years 44.9 (27.9) 55.6 (29.4) <0.0001
Current smokers 101 (22.7%) 29 (17.5%) 0.26
Dyspnea <0.0001
I 43 (9.7%) 1 (0.6%)
II 243 (54.6%) 63 (37.9%)
III 147 (33.0%) 86 (51.8%)
IVeV 12 (2.7%) 16 (9.6%)
COPD severity, n (%) <0.0001
GOLD staging II 249 (56%) 55 (33.1%)
GOLD staging III 182 (40.9%) 85 (51.2%)
GOLD staging IVeV 14 (3.15%) 26 (15.7%)
Saint George’s Respiratory Questionnaire (SGRQ)
Activity 50.4 (21.1) 62.0 (18.6) <0.0001
Impact 30.4 (19.5) 38.9 (17.5) <0.0001
Symptoms 40.5 (20.9) 47.0 (20.7) 0.0005
Total SGRQ 38.2 (18.2) 47.3 (16.1) <0.0001
Hospitalisations in the 2 years prior to baseline, n (%) <0.0001
0 309 (69.4%) 78 (47%)
1e2 115 (25.8%) 62 (37.3%)
3 21 (4.7%) 26 (15.6%)
Comorbidities, n (SD) 1.6 (1.25) 1.5 (1.20) 0.37
Data are presented as mean (SD) or number (%).
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FEV1%, FEV1 as a percentage
of the predicted value; SGRQ, Saint George’s Respiratory Questionnaire; VC, vital capacity.
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years and the other relevant variables, student’s t-test
and the Wilcoxon test were used for continuous vari-
ables and Chi-Square and Fisher’s exact tests for cate-
gorical variables.
Patients were grouped into three categories: those
not hospitalised for a COPD exacerbation during the 5-
year study period, those hospitalised 1e2 times, and
those hospitalised 3 times. To explore differences
among the three hospitalisation categories and the
HRQoL domains, as well as for other continuous vari-
ables, we used ANOVA with the Scheffe´ test for multiple
comparisons. For evaluating categorical variables across
the three hospitalisation categories we used the Chi-
Square test. The paired t-test was used to determine if
changes occurred in HRQoL from baseline to the study’s
end, 5 years later.
General linear models were used in the multivariate
analysis. The change in HRQoL, measured by the total
SGRQ, the SF-36 physical component summary scale (PCSS),
and the SF-36 mental component summary scale (MCSS),
were the dependent variables in three different models.
The main independent variable was hospitalisations for
COPD during follow-up categorized as no hospitalisation
(baseline category), 1e2, and 3 hospitalisations. Other
independent variables were HRQoL in the same domain at
baseline, FEV1 as a percentage of the predicted value
(FEV1%), comorbidities and age.All effects were considered significant at p< 0.05 unless
otherwise noted. All statistical analyses were performed
using SAS for Windows statistical software, version 8.2 (SAS
Institute, Inc., Carey, NC).Results
A total of 611 patients were recruited for the study. After 5
years of follow-up, 166 (27.2%) patients had died. Among
the 445 patients alive after 5 years of follow-up, 54 patients
were not included in the final analysis: 25 had active
neoplasms, 19 had moved out of the area, 7 had developed
psychiatric disorders or Alzheimer’s disease, 1 became
blind, and 2 could not be located. The characteristics of
these 54 patients were not different from the rest of the
patients who survived. This left 391 patients for inclusion in
the study.
The baseline characteristics of the original cohort of 611
patients are shown in Table 1. Patients who died during the
course of the study were older, had lower mean FEV1,
smoked more, had lower HRQoL, and had been admitted to
the hospital more often in the 2 years before the study than
those who were alive after 5 years.
Of the 391 patients included in the final cohort, 287 (73.4%)
had not been admitted to the hospital during the 5-year
follow-up, 76 (19.4%) were admitted 1e2 times, and 28 (7.2%)
were admitted 3 ormore times. The general characteristics of
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the hospital had a lower FEV1 at baseline (p< 0.0004).
HRQoL at baseline and after 5 years of follow-up are
listed in Table 3, grouped by the number of hospital-
isations during the study period. Differences in SGRQ
scores of more than 4 units were considered as clinically
significant differences. We observed clinically significant
differences in baseline HRQoL assessed by the total SGRQ
score between participants who did not have any hospi-
talisations during follow-up and those who had at least
one hospital admission. There were also differences
between the group with 3 admissions and those without
any, but they were not statistically significant owing to
the small size (28 patients) of the group with 3 hospi-
talisation. Patients with 1e2 admissions who had SGRQ
scores similar to those in the group with 3 hospital-
isations showed statistically and clinically significant
differences (higher than 4 units in SGRQ scores) in all
areas except for the ‘‘impact’’ area compared with those
without any hospitalisations. No statistically or clinically
significant differences were found at baseline between
those with 1e2 hospitalisations during the follow-up
period and those hospitalised 3 times. Similar patterns
were seen in the ‘‘symptoms,’’ ‘‘impact,’’ and ‘‘activity’’
domains of the SGRQ.
After 5 years of follow-up, statistically significant
differences were observed in SGRQ scores among the
three groups of patients. Patients who were not hospi-
talised during the study period showed a statistically
significant 3.7-point improvement in ‘‘activity,’’ while no
clinically or statistically significant changes were
observed in the other areas of the SGRQ. Among patientsTable 2 Baseline characteristics of participants who survived at
Hospitalisations 0 1e
Number (%) 287 (73.4%)
Age (years) 65.2 (8.8) 66
FEV1 (L) 1.52 (0.47) 1.
FEV1% 53.9 (13.7) 49
FEV1/VC (%) 50 (10.32) 51
BMI (kg/m2) 27.8 (4.0) 28
Pack/years 45.3 (29.1) 39
Current smokers 58 (20.2)
Dyspnea, n (%)
I 32 (11.2%)
II 163 (57%)
IIIeV 91 (31.7%)
COPD severity, n (%)
GOLD staging II 172 (60.1%)
GOLD staging III 110 (38.5%)
GOLD staging IVeV 4 (1.4%)
Hospitalisations in the 2 years prior to baseline, n (%)
0 220 (76.6%)
1e2 57 (19.9%)
>3 10 (3.5%)
Comorbidities, n (SD) 1.6 (1.26) 1
Data are presented as mean (SD) or number (%).
BMI, body mass index; COPD, chronic obstructive respiratory disease; F
of the predicted value; SGRQ, Saint George’s Respiratory Questionnahospitalised 1e2 times during the study, SGRQ scores
declined in all areas except ‘‘activity,’’ although the
differences were not clinically or statistically significant
different. Patients hospitalised 3 times showed clini-
cally and statistically significant declines in HRQoL,
expressed by a 13.6 increase in the total SGRQ.
HRQoL at baseline as determined by the SF-36 was
similar across the 3 groups in the PCSS and MCSS. After 5
years of follow-up, the PCSS showed statistically significant
declines in all 3 groups, with greater declines in HRQoL
among patients who were hospitalised at any point during
the study period (Table 3).
FEV1 at baseline was lower among patients who were
hospitalised at some point during the follow-up period.
After 5 years of follow-up, FEV1 had increased in all
three groups; the improvement was statistically signifi-
cant only for those patients who were not hospitalised
(Table 3).
Comorbidities increased during 5 years follow-up, from
an average of 1.6e2.3 for patients with 0 hospitalisations,
1.6e2.3 for patients with 1e2 hospitalisations, and 1.5e2.4
for patients with 3 hospitalisations. Although the
increases in comorbidities was statistically significant (1.6
mean comorbidities at baseline vs 2.3 at 5 years
[p< 0.0001]), there were no differences across the three
groups after 5 years of follow-up.
Among patients with FEV1% 50% at baseline, a clinically
significant difference was observed in total SGRQ between
patients who were not hospitalised over the study period
and those who were (Table 4).
After 5 years of follow-up, clinically and statistically
significant declines were observed in all areas of the SGRQleast 5 years by number of hospitalisations during follow-up.
2 3 p
76 (19.4%) 28 (7.2%)
.6 (7.4) 64.9 (8.8) 0.14
35 (0.44) 1.24 (0.38) 0.0004
.5 (13.7) 44.6 (13.3) 0.0004
.1 (10.2) 47.3 (10.1) <0.0001
.6 (5.4) 28.6 (4.6) 0.24
.0 (24.8) 45.9 (23.7) 0.20
18 (23.7) 9 (32.1) 0.10
0.08
4 (5.3%) 3 (10.7%)
36 (47.4%) 13 (46.4%)
36 (47.3%) 12 (42.9%)
0.01
39 (51.3%) 12 (42.9%)
33 (43.4%) 13 (46.4%)
4 (5.3%) 3 (10.7%)
<0.0001
43 (56.6%) 13 (46.4%)
31 (40.8%) 9 (32.1%)
2 (2.6%) 6 (21.4%)
.6 (1.25) 1.5 (1.20) 0.37
EV1, forced expiratory volume in 1 s; FEV1%, FEV1 as a percentage
ire; VC, vital capacity.
Table 3 HRQoL at baseline and after 5 years of follow-up by the number of hospitalisations.
Hospitalisations 0a 1e2b 3c p-Value 0a 1e2b 3c p-Value
Baseline After 5 years of follow-up
SGRQ
Activity 47.6 (20.4)b,c 57.2 (22.9)a 58.1 (20.5)a 0.0003 44.0 (24.1)b,c,* 55.4 (25.3)a,c 69.1 (21.9)a,b,* <0.0001
Impact 28.7 (19.0) 34.0 (19.7) 34.8 (17.7) 0.04 28.6 (20.9)b,c 37.8 (21.3) a,c 49.6 (22.4)a,b,* <0.0001
Symptoms 37.9 (20.8)b 46.7 (21.3)a 47.0 (18.0) 0.001 39.0 (22.1)b,c 50.3 (21.0)a,c 61.8 (19.2)a,b,* <0.0001
Total 36.0 (17.7)b 43.1 (18.9)a 43.9 (16.4) 0.002 35.0 (19.9)b,c 45.2 (19.5)a,c 57.5 (19.5)a,b,* <0.0001
SF-36
PCSS 46.2 (8.0) 44.2 (7.9) 45.2 (6.0) 0.13 41.1 (8.7)b,c,* 37.4 (8.9)a,* 34.7 (7.8)a,* <0.0001
MCSS 49.9 (11.3) 50.3 (10.6) 49.7 (10.0) 0.96 51.5 (11.3)c,* 50.9 (11.5) 45.6 (13.3)a 0.03
Physical functioning 67.8 (21.2)b 57.8 (22.2)a 58.7 (19.6) 0.0004 60.7 (24.6)b,c,* 45.7 (26.5)a,* 35.5 (22.9)a,* <.0001
Role physical 79.1 (35.4) 78.0 (33.9) 82.1 (33.2) 0.86 70.1 (36.4)* 63.1 (38.6)* 58.9 (42.1)* 0.16
Bodily pain 70.7 (27.6) 71.8 (27.4) 76.2 (25.3) 0.59 70.7 (28.8) 69.1 (30.1) 65.7 (30.5) 0.65
General health 49.0 (22.2) 46.8 (22.5) 42.5 (20.0) 0.26 46.4 (22.1)c,* 40.3 (21.6)c,* 27.5 (17.9)a,b,* <0.0001
Vitality 64.8 (23.8) 58.2 (22.2) 58.7 (23.8) 0.06 62.4 (24.3)c 57.2 (22.8)c 40.9 (26.6)a,b,* <0.0001
Social functioning 83.2 (22.6) 85.5 (20.9) 90.6 (13.4) 0.18 83.1 (24.0)c 78.9 (26.8) 67.0 (33.2)a,* 0.004
Role emotional 83.3 (34.7) 84.2 (34.2) 73.8 (38.9) 0.35 83.1 (33.0) 80.7 (36.2) 70.2 (40.9) 0.15
Mental health 77.1 (22.2) 75.5 (20.2) 78.4 (17.4) 0.77 75.5 (24.1) 71.7 (23.2) 64.4 (27.4)* 0.04
FEV1 (L) 1.52 (0.47)
b,c 1.35 (0.44)a 1.24 (0.38)a 0.0004 1.61 (0.71)* 1.62 (0.70) 1.26 (0.63) 0.13
Data are presented as mean and standard deviation. Superscript letters indicated differences among the three hospitalisation categories
by Scheffe´ test for multiple comparisons at p< 0.05 for continuous variables.
FEV1, forced expiratory volume in 1 s; HRQoL, health-related quality of life; MCSS, mental component summary of SF-36; PCSS, physical
component summary of SF-36; SGRQ, Saint George’s Respiratory Questionnaire.
* p< 0.05 change between baseline and after 5 years.
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who were hospitalised during the study period compared
to those who were not. Moreover, impairment in HRQoL
was significantly greater in patients with 3
hospitalisations.Table 4 HRQoL at baseline and after 5 years of follow-up by th
Hospitalisations 0a 172 1e2b 39 3c 12 p-V
Baseline
SGRQ
Activity 44.3 (20.3) 49.9 (21.6) 53.6 (25.5) 0.1
Impact 26.2 (18.6) 29.3 (16.9) 33.0 (16.2) 0.3
Symptoms 35.4 (20.2) 42.8 (20.8) 42.5 (17.8) 0.0
Total 33.3 (17.4) 37.8 (16.9) 40.8 (17.3) 0.1
SF-36
PCS1 47.2 (7.5) 45.5 (7.6) 45.1 (7.1) 0.3
MCS1 49.6 (11.6) 47.6 (12.2) 48.6 (9.3) 0.6
Physical functioning 69.9 (20.4)b 60.6 (21.6)a 58.3 (22.0) 0.0
Role physical 82.6 (33.8) 79.5 (32.9) 83.3 (34.3) 0.8
Bodily pain 68.9 (28.7) 66.4 (28.7) 76.0 (22.8) 0.5
General health 52.0 (22.3) 50.6 (24.2) 41.0 (13.4) 0.2
Vitality 67.1 (23.6) 57.0 (21.0) 50.8 (24.3) 0.0
Social functioning 83.9 (22.4) 82.0 (24.5) 91.7 (15.4) 0.4
Role emotional 81.2 (36.2) 77.8 (40.0) 75.0 (35.2) 0.7
Mental health 76.9 (22.4) 71.7 (21.7) 75.7 (17.4) 0.4
FEV1 (L) 1.78 (0.38) 1.65 (0.35) 1.54 (0.34) 0.0
Data are presented as mean and standard deviation. Superscript letter
by Scheffe´ test for multiple comparisons at p< 0.05 for continuous v
FEV1, forced expiratory volume in 1 s; HRQoL, health-related quality o
component summary of SF-36; SGRQ, Saint George’s Respiratory Que
* p< 0.05 change between baseline and after 5 years.In the multivariate analysis of the different models using
total SGRQ and the SF-36 PCSS and MCSS as dependent
variables (Table 5), after adjustment by FEV1%, age,
comorbidities, and baseline HRQoL, the number of hospi-
talisations was independently associated with declines ine number of hospitalisations in patients with FEV1% 50%.
alue 0a 172 1e2b 39 3c 12 p-Value
After 5 years of follow-up
3 39.7 (22.7)b,c,* 52.4 (24.0)a 62.4 (26.9)a <0.0001
3 24.9 (19.8)b,c 37.5 (21.0)a,* 49.1 (24.2)a <0.0001
7 36.9 (21.5)b,c 47.6 (19.1)a 63.7 (19.7)a,* <0.0001
4 31.4 (18.5)b,c 43.7 (18.5)a,* 55.6 (22.7)a <0.0001
2 41.9 (8.9)b,c,* 38.1 (9.2)a,* 34.8 (8.5)a,* 0.004
3 52.0 (11.1)c,* 50.3 (11.5)c 40.6 (14.3)a,b 0.003
1 63.8 (23.8)b,c,* 48.8 (27.0)a,* 40.0 (22.8)a,* <0.0001
6 73.4 (35.2)* 64.1 (41.3) 50.0 (42.6)* 0.05
9 68.1 (30.6) 63.0 (31.8) 63.1 (34.3) 0.58
5 49.5 (21.6) 43.3 (21.2)* 19.6 (13.0)* <0.0001
07 64.7 (23.0) 59.9 (19.9) 34.2 (29.1) <0.0001
3 84.4 (22.3) 78.5 (23.5) 59.4 (35.8)* 0.001
6 85.1 (31.3) 79.5 (38.7) 55.5 (45.7) 0.01
1 76.2 (23.7) 69.5 (22.3) 59.3 (26.9)* 0.02
2 1.80 (0.53) 1.66 (0.41) 1.49 (0.49) 0.08
s indicated differences among the three hospitalisation categories
ariables.
f life; MCSS, mental component summary of SF-36; PCSS, physical
stionnaire.
Table 5 Multivariate analysis of influence of hospitalisations for COPD exacerbations on changes in HRQoL after 5 years of
follow-up.
Total-SGRQ PCSS MCSS
B-estimate p-Value B-estimate p-Value B-estimate p-Value
Number of hospitalisations
0 Ref. Ref. Ref.
1e2 4.921 0.01 2.742 0.004 0.470 0.72
3 15.323 <0.0001 5.228 0.0005 5.001 0.01
FEV1% 0.179 0.002 0.026 0.35 0.080 0.03
Baseline same domain HRQoL 0.368 <0.0001 0.537 <0.0001 0.527 <0.0001
Comorbidities 1.638 0.01 1.450 <0.0001 1.117 0.009
Comorbidities at 5 years 2.447 0.009 2.251 <0.0001 0.805 0.20
FEV1, forced expiratory volume in 1 s; HRQoL, health-related quality of life; MCSS, mental component summary of SF-36; PCSS, physical
component summary of SF-36; SGRQ, Saint George’s Respiratory Questionnaire.
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specific SGRQ. When using the more general SF-36, PCSS
scores were independently associated with hospital
admissions while MCSS scores were independently associ-
ated with hospitalisation for COPD exacerbations only
among patients with 3 admissions. Other variables eval-
uated, such as hospital admissions in the 2 years before the
start of the study, BMI, and pack/years of cigarettes, did
not have any influence on the results.Discussion
Among typical patients with COPD, those who did not have
exacerbations severe enough to require hospitalisation over
a 5-year period did not suffer significant deterioration in
HRQoL. In contrast, patients with exacerbations severe
enough to require hospital admission experienced declines
in HRQoL independent of the FEV1%, age, comorbidities,
and, most important, baseline HRQoL. Declines in HRQoL
were observed regardless of the initial severity of the
disease, as measured by FEV1%, even among patients with
FEV1 50% of the predicted value. As might be expected,
patients hospitalised 3 times experienced the largest
declines in HRQoL.
Associations between both the frequency of COPD
exacerbations and hospital admissions in the previous year
with impairment of HRQoL has been well established.13,21
However, it has not been possible in these studies to
establish causality, since HRQoL was measured after the
exacerbations and admissions had taken place.
Studies with different designs than the two previously
mentioned have corroborated our findings. For example,
Miravitlles et al.14 found that patients with moderate
COPD who experienced 3 exacerbations during 2 years
suffered a larger loss of HRQoL (2 units/year) than
patients with severe COPD and <3 exacerbations. In the
Inhaled Steroids in Obstructive Lung Disease in Europe
(ISOLDE) study, patients with frequent exacerbations
(>1.65/year) had the greatest impairment in HRQoL (2.9
units/year).4 These studies support the importance of
exacerbations in the deterioration of HRQoL. Although
only a small proportion (5.9%) of patients who sufferexacerbations of COPD require hospital admission,6 the
long-term impact of these hospitalisations on HRQoL has
not yet been established. In our study, patients with 3
hospitalisations during 5 years of follow-up had the
largest decreases in HRQoL regardless of whether their
FEV1% was above or below 50%. This differs with the
results of Miravitlles et al.,14 most likely because all
patients in their cohort had FEV1%< 50% as all the
participants were recruited from secondary and tertiary
hospitals. In contrast, our patients were recruited from
outpatient clinics and consequently had less severe
COPD. In addition, the close clinical follow-up in the
study by Miravitlles et al. may have accounted in part
for the improvement observed in HRQoL, whereas in our
study, which was longer, patient care was wholly at the
discretion of treating physicians and was not influenced
by this research. Thus it reflected actual clinical
practice.
An important finding from our study is that HRQoL, as
measured by the respiratory-specific SGRQ, did not
measurably change over 5 years of follow-up among
patients who had not been hospitalised for an exacerbation
of COPD. This contrasts with the findings of Spencer et al.,4
in which COPD patients who did not suffer exacerbations
continued losing HRQoL (2 SGRQ units/year) independent of
FEV1 deterioration. Of note, their study was a clinical trial
with set protocols, whereas the respiratory specialists for
the patients participating in our study had the option to
alter treatment as needed. The stability we observed in
HRQoL and FEV1 among nonhospitalised patients is likely
due to changes in clinical practice, such as the introduction
of new drugs like tiotropium22 and the combination of long-
acting b2 agonists with inhaled corticosteroids. In both the
Spencer4 and Miravitlles14 studies, the investigators ana-
lysed exacerbations treated in outpatient clinics together
with those requiring hospitalisation. Consequently, it is
impossible to determine from these studies if both types of
exacerbation had similar impacts or whether those result-
ing in hospitalisation had more profound effects on the
deterioration of HRQoL.
In our study, the generic SF-36 recorded impairment in
areas such as ‘‘physical functioning’’, ‘‘general health’’
and the PCSS across all three categories of hospitalisation.
Hospitalisations for COPD exacerbations and HRQoL 1207This likely reflects the natural decline in HRQoL with
increasing age and the impact of new comorbidities that
appeared during the 5-year follow-up period.
An interesting aspect of our study is that the severity of
COPD at baseline, as measured by FEV1%, did not influence
the impact of hospitalisations on HRQoL. Similar declines in
HRQoL were observed among patients with FEV1% 50% at
baseline and those with FEV1%< 50% who were hospitalised
for one or more exacerbations. To the best of our knowl-
edge, this has not been previously reported.
Among the patients in our study, decreases in HRQoL
were not related to corresponding decreases in FEV1, sug-
gesting that other variables play important roles in the
evolution of HRQoL among patients hospitalised for COPD
exacerbations. Systemic changes associated with COPD may
be one possibility. Exacerbations of COPD have been asso-
ciated not only with inflammation of the lower airway but
also with systemic inflammation.23 In hospitalised COPD
patients, peripheral muscle weakness intensified during the
exacerbation and quadriceps peak torque was inversely
correlated with systemic interleukin-8.24 Moreover, after
hospitalisation for exacerbation of COPD, active time
(walking time plus standing time) was positively and
significantly correlated to the quadriceps force.25 Whether
systemic inflammation, muscle strength, loss of physical
activity or other factors contribute to the decline in HRQoL
we observed, and whether they persist over time, remain to
be answered.
Our study has several strengths, including its long
duration (5 years of follow-up). Since the population
included a general sample of COPD patients, not just hos-
pitalised patients, the results should be generalisable to
many individuals with COPD. Another important aspect of
our study is that the patients did not undergo any special
study-related treatments during the follow-up period.
Instead, they continued to follow the controls and treat-
ments prescribed by their pneumologists, who did not
receive any direction regarding treatment from the study
authors. As such, the results reflect common clinical prac-
tice rather than the more tightly scripted medical care
required in clinical trials.
The limitations of our study must also be noted. The
relatively small number of patients with 3 hospitalisations
(7.2%), especially in the FEV1% 50% group, limits the
ability to detect statistically significant differences.
However, the median differences observed are clinically
important. We were not able to determine the impact of
exacerbations that did not require hospitalisation, since
the study was not designed to focus on such patients. Doing
so would have required a more complex study with the use
of daily diary cards13 or other instruments. We recorded
HRQoL only at baseline and after 5 years, not throughout
the course of the study. Routine measurements of HRQoL
would have provided more information about the evolution
of HRQoL in relation to hospital admission. Another limi-
tation of our study is that we were unable to include in the
final analysis the relatively large number of patients (166)
who died during follow-up, since we did not have final
assessments of HRQoL for them. It is likely that this
diminished the impact of hospitalisations on HRQoL, since
these patients experienced the largest number of hospi-
talisations. Our patient population was almost entirelycomposed of men (97.7%), which reflects the current
distribution of COPD in Spain, where women did not begin
to smoke until late in the 20th century. Similar gender
distributions have been observed in other studies per-
formed in Spain.11 Although the high percentage of men
included in the study does not imply any selection bias or
affect the validity of the results, it does limit their
generalisability.
Establishing a precise causal relationship between hos-
pitalisations for COPD exacerbation and deterioration in
HRQoL parameters would require a more complex design
and extremely close follow-up of patients, such that it
would be possible to determine HRQoL status in the days
prior to each index readmission and, then, to record the
change in HRQoL parameters in the days or week after
discharge. Nevertheless, our conclusions seem valid since
a loss in HRQoL status can reasonably be expected after
a hospitalisation for an exacerbations for COPD.
In conclusion, the results of this study indicate that
severe acute exacerbations of COPD leading to hospital-
isation have a substantial impact on HRQoL among patients
who survived for at least 5 years, independent of their
baseline FEV1 and HRQoL. The more hospitalisations, the
more serious the impairment in HRQoL. Identifying patients
who are most likely to be hospitalised for a COPD exacer-
bation and establishing measures to prevent exacerbations
or treating them early and aggressively to avoid hospital-
isation, even in patients with milder COPD (FEV1% 50%),
could slow or prevent the loss of HRQoL.
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